The Institut Pasteur announced on Monday that it was halting the development of its main vaccine project against Covid-19, the one based on measles, because the first tests showed that it was less effective than hoped. Further work is in progress, however at a preliminary stage.
After the difficulties of Sanofi, those of the Pasteur Institute. This French player in the fight against Covid-19 announced, in a press release published on Monday, January 25, the abandonment of the development of his main vaccine project on which he had been working for months.
"Following interim results from a phase I clinical trial, the Institut Pasteur is halting the development of one of its vaccine candidates, the one based on the measles vaccine virus," explains the private French foundation. And to continue: "This decision does not call into question the continuation of the research undertaken on two other candidate vaccines based on different methodologies."
Another French actor, the Sanofi laboratory, announced in December that its vaccine was late and would not be ready until the end of 2021, due to less good results than expected.
In the case of Pasteur's vaccine, "the induced immune responses were found to be lower than those observed in people cured of a natural infection as well as those observed with authorized vaccines" against Covid-19, explained the Institute to justify its decision to terminate its project.
Other vaccine projects at an early stage
To design and distribute it, the French research institute joined forces with the MSD pharmaceutical laboratory - the name of the American group Merck outside the United States and Canada. MSD had, in fact, bought last year the Austrian biotechnology company Themis, with which Pasteur has been working for several years on the development of various vaccines, including that against Covid-19.
إرسال تعليق